Ars Pharmaceuticals Inc (SPRY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2017 | 12-2006 | 12-2005 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 386,569 | 9,976 | N/A | N/A | N/A |
| TOTAL | $390,656 | $10,528 | $N/A | $N/A | $N/A |
| Non-Current Assets | |||||
| PPE Net | 1,618 | 1,316 | N/A | N/A | N/A |
| Other Non-Current Assets | 2,530 | 3,803 | 0 | 0 | 0 |
| TOTAL | $4,148 | $5,119 | $N/A | $N/A | $N/A |
| Total Assets | $394,804 | $15,647 | $N/A | $N/A | $N/A |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 844 | 1,522 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | 2,583 | 3,518 | 0 | 0 | 0 |
| Accrued Expenses | 5,278 | 2,112 | N/A | N/A | N/A |
| TOTAL | $9,601 | $17,926 | $N/A | $N/A | $N/A |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 2,326 | 3,324 | 0 | 0 | 0 |
| TOTAL | $2,326 | $3,324 | $N/A | $N/A | $N/A |
| Total Liabilities | $11,927 | $21,250 | $N/A | $N/A | $N/A |
| Shareholders' Equity | |||||
| Common Shares | 3 | N/A | N/A | N/A | N/A |
| Retained earnings | -96,734 | -63,787 | N/A | N/A | N/A |
| Other shareholders' equity | 0 | 53,174 | 0 | 0 | 0 |
| TOTAL | $382,877 | $-5,603 | $N/A | $N/A | $N/A |
| Total Liabilities And Equity | $394,804 | $15,647 | $0 | $0 | $0 |